CellAI seeks accredited investors who invest in early-stage life sciences software and have a desire to demystify disease.
Investor Presentation
Welcome to CellAI
We’re developing 3D spatial biology software capable of 3D cell phenotyping. Researchers can use our software to unlock data that was previously not available in their datasets. Our aim is to demystify disease.
My name is Al Hansen, president and founder. Please reach out with any questions.
The Problem
Researchers need to escape 2D flat biology and gain access to real world 3D biological data
There is still a poor understanding of the tumor microenvironment
90% of the drugs conceived never make it to the medicine cabinet
It is data that can advance scientific research, not pretty pictures alone
The Solution
The solution is spatial biology with underlying quantitative data. At CellAI, we make the invisible, visible. We show the context. We show the numbers.
We provide a blueprint and quantitative data to understand biology in three dimensions:
to understand the tumor microenvironment
to know whether a drug is working or not
to see what’s going on in the cellular neighborhood
CellAI Technology
Our software is platform agnostic and works with microscopes and instruments that capture high resolution, 3D images of tissues. It doesn’t matter whose microscope, or which instrument the images come from.
These images use fluorescent labeling to reveal the presence of different biomarkers.
CellAI reveals the 3D spatial relationships and the quantitative data that scientists need to advance their research.
What Scientists are Saying about 3D Spatial Biology
“Looking at the immune cell infiltration and migration patterns in three-dimensional space would be really informative to disease progression.”
Priyank Patel, PhD
Senior Scientist, Boehringer Ingelheim
“Spatial tissue profiling has a new name now - but in a few years it will be for healthcare just Pathology.”
Ioannis Vlachos
Spatial Technologies Unit, Harvard Medical School, BIDMC, Broad Institute of MIT & Harvard
The solutions landscape spans discovery, translational research, and reaches into the clinic.
It all starts with a tissue. That tissue is imaged or scanned, and its digital representation can be further analyzed in software. Digital pathology takes this practice into the clinic.
CellAI Key Advantages
3D Spatial Biology Focus
Platform Agnostic
Quantitative analysis
3D cell phenotyping
3D quantitative data
Handles large datasets
Scientists use numerous software solutions within their organizations. Software solutions are a mix of commercial, open source and in some cases home grown, DIY solutions.
Market Size
The current market for 3D image analysis is very small. We believe this is because there are no commercial solutions to analyze large 3D datasets. We estimate the total addressable market at about $7 billion, with about $2 billion pre-clinical. Details available on request.
Milestones
Acquired software IP portfolio and development team from ClearLight Biotechnologies
Started up CellAI, Inc. to address unmet need for commercial solution to empower researchers with decision making around large 3D datasets and quantitative analysis
Identified first alpha customer and worked on the first external dataset to test the software and workflow
Seeking investment to continue product development and gain customer feedback
Favorable Exits in the Life Sciences Software Tools
CellAI seeks accredited investors who invest in early-stage life sciences software. Use of funds will be to further develop software, expand alpha customers, and tune workflow and deep learning model to fit new customers.
Summary
Current addressable market $7B+
IP Strategy – AI + trade secret + first mover in 3D
Large installed based of 3D microscopes
Significant milestones already achieved
Comparables show strong strategic interest and exits
Experienced team in place for 1 year +
Early customer traction
Convertible note offering with lead investor founder